Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03816683 · ClinicalTrials.gov registry record
A Disease Registry of Patients With Mantle Cell Lymphoma
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 227
- Enrollment target
NCT03816683 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 227 participants.
The verdict
NCT03816683 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 227 participants
- Enrollment target
Study Summary
The purpose of this study is to create a patient registry in order to assess treatment patterns, physician reported clinical outcomes and patient-reported health-related quality of life among patients diagnosed with Mantle Cell Lymphoma (MCL) who newly initiated a novel therapy in the past 6 months and whose treatment is ongoing at the time of enrollment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2024-03-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03816683
The ClinicalTrials.gov registry entry for NCT03816683 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03816683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03816683 about?
NCT03816683 is a clinical study titled "A Disease Registry of Patients With Mantle Cell Lymphoma". The purpose of this study is to create a patient registry in order to assess treatment patterns, physician reported clinical outcomes and patient-reported health-related quality of life among patients diagnosed with Mantle Cell Lymphoma (MCL) who newly initiated a novel therapy in the past 6 months ...
What is the current status of trial NCT03816683?
This trial is currently completed. The enrollment target is 227 participants. The study started on 2019-04-01. Estimated completion is 2024-03-18.
Who is sponsoring clinical trial NCT03816683?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.